G-CSF administration in acute myocardial infarction: what is the best timing? Reply
We welcome the interest of Maggiolini and colleagues in our recent article on granulocyte colony-simulating factor (G-CSF) in acute myocardial infarction (AMI), 1 arguing for early (hours rather than days) G-CSF administration in relation to its observed beneficial effects in functional recovery post-AMI. Indeed, mixed outcomes from clinical trials point to several outstanding issues that await further investigation. Chief among them is a clinically practicable window of G-CSF administration for cytokine-mobilized stem cell therapy. We agree with the authors that meta-analysis has indicated a positive correlation between G-CSF timing and left ventricular ejection fraction (LVEF) outcome, though current available literature on this topic remains controversial and consensus has yet to emerge. The crux of the issue stems from the following issues: Overgaard et al. 16 had previously demonstrated insensitivity of LV functional recovery to G-CSF timing, carefully designed and well-controlled randomized trials that are adequately sample sized for subgroup analysis in this respect would be highly anticipated.
